Contact this trialFirst, we need to learn more about you.
CAR T-cell Therapy
Engineered T Cells for Blood Cancer
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial will test if it is safe to give HSCT recipients T cells that have been engineered to kill tumor cells. It will also test if this treatment improves the six-month event-free survival rate for patients with high-risk AML or MDS.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service